Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$0.36
+2.9%
$0.30
$0.17
$2.04
$52.76M0.972.49 million shs1.47 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19172,213 shs4.12 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.43
+3.7%
$5.82
$2.61
$7.79
$567.93M1.951.07 million shs1.02 million shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$2.88
-1.4%
$2.16
$1.37
$9.13
$108.49M0.99178,376 shs166,338 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+9.61%+11.93%+33.59%-28.57%-80.23%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%0.00%-71.49%
Personalis, Inc. stock logo
PSNL
Personalis
+0.16%-4.17%-3.43%+81.82%+61.04%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00%+5.80%+52.08%-16.09%-62.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biodesix, Inc. stock logo
BDSX
Biodesix
3.5338 of 5 stars
4.45.00.00.00.02.50.6
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
3.0746 of 5 stars
2.51.00.04.20.62.50.6
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.2569 of 5 stars
0.02.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.80
Moderate Buy$1.75386.11% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.6719.23% Upside
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PSNL, ENZ, SERA, and BDSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.00
5/15/2025
Personalis, Inc. stock logo
PSNL
Personalis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.50 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
5/7/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
4/29/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.50 ➝ $2.50
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$71.32M0.74N/AN/A$0.14 per share2.57
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Personalis, Inc. stock logo
PSNL
Personalis
$85.69M6.63N/AN/A$2.87 per share2.24
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$80K1,356.12N/AN/A$1.40 per share2.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$42.93M-$0.29N/AN/AN/A-54.28%-167.28%-39.96%8/6/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Personalis, Inc. stock logo
PSNL
Personalis
-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)

Latest PSNL, ENZ, SERA, and BDSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.07N/AN/AN/A$18.47 millionN/A
8/6/2025Q2 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.25N/AN/AN/A$20.12 millionN/A
8/6/2025Q2 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.21N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million
5/13/2025Q1 2025
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
3.32
2.22
2.22
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.91
6.74
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.02
2.02

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
30.10%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
220146.56 million102.45 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.33 million84.97 millionOptionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.67 million31.72 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$0.36 +0.01 (+2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 +0.01 (+1.39%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Personalis stock logo

Personalis NASDAQ:PSNL

$6.43 +0.23 (+3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$6.42 -0.01 (-0.22%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$2.88 -0.04 (-1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$2.97 +0.09 (+3.09%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.